Development of Plasmid DNA-based Vaccines for Treatment and Prevention of Infectious Disease
Industrial Strength Bio Seminar Series
Dr. Sean Sullivan, Executive Director of Pharmaceutical Sciences, Vical Inc., will give a brief summary of Vical's clinical development program, discuss development of the avian flu vaccine from preclinical to clinical development, go over some preliminary results from our Herpes Simplex 2 vaccine program, and discuss technology on the large scale (0.75L) enzymatic synthesis of DNA.
Dr. Sullivan has a MS degree in Biochemical Enzymology and a Ph.D. in membrane biophysics. He has been in the biotechnology industry for over 20 years and has worked for companies in different stages of development ranging from startups to late stage clinical development. His role has been to develop lipid- and polymer-based drug delivery systems for antisense DNA, ribozymes and plasmid DNA. As Executive Director of Pharmaceutical Sciences, he manages the department responsible for development and scale up of plasmid DNA formulated with either lipids or polymers to be used a prophylactic vaccines or immunotherapies. Prior to joining Vical, Dr. Sullivan was a tenured associate professor at the University of Florida College of Pharmacy with a joint appointment at Shands Cancer Institute.
This is a BYOL (Bring Your Own Lunch) event. For more information, contact Diana Bartlett, Diana.bartlett[at symbol]kgi.edu, (909) 607-9864.
|Where:||KGI Main Campus, 517 Lecture Hall|
|When:||December 7, 2010, 12:00 p.m. - 1:00 p.m.|